Welcome!

News Feed Item

Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2014

Second quarter net earnings per diluted share are $0.88 including patent litigation settlement; revenues increase 1 percent to $779 million

PALO ALTO, Calif., April 23, 2014 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today is reporting net earnings of $0.88 per diluted share in the second quarter of fiscal year 2014, including a $0.16 charge per diluted share related to a previously announced settlement of patent litigation.  Varian's company-wide revenues totaled $779 million for the second quarter of fiscal year 2014, up 1 percent from the year-ago quarter.  Varian ended the second quarter with a $2.8 billion backlog, up 2 percent from the end of the second quarter of fiscal year 2013.

"Gross orders rose strongly in our imaging components and proton businesses on top of mid-single-digit gains in Oncology Systems," said Dow R. Wilson, CEO of Varian Medical Systems.  "Revenues came in slightly ahead of expectations versus a strong year-ago comparison, and our overall growth strategy remained on track."

The company finished the second quarter of fiscal year 2014 with $939 million in cash and cash equivalents and $469 million of debt.  Cash flow from operations for the fiscal second quarter was $126 million.  During the quarter, the company spent $159 million to repurchase approximately 2 million shares of its common stock.

Oncology Systems
Oncology Systems' second quarter revenues totaled $603 million, up 4 percent from the same quarter of fiscal year 2013.  Second-quarter gross orders were $613 million, up 6 percent versus the year-ago quarter, with a 3 percent gain in North America and a 9 percent gain outside North America. Markets outside North America represented 58 percent of Oncology gross orders for the second quarter of fiscal year 2014. 

"Gross orders rose versus the year-ago quarter in North America with the help of good service growth.  New multi-year agreements with large hospital systems also contributed to gains in Oncology products and services," Wilson said.  "International orders increased with particular strength in Latin America and Australia that offset softness in Asia.  Initiatives to expand our radiosurgery business and stimulate replacement of aging Siemens units gained traction during the quarter."

Imaging Components
During the second quarter, the company consolidated its X-Ray Products and Security and Inspection Products businesses into a single Imaging Components segment to conform to an organizational change. Second quarter revenues for Imaging Components were $169 million, up 2 percent from the year-ago quarter.  Imaging Components second quarter gross orders were $205 million, up 14 percent from the year-ago quarter. "Strong panel business drove order and revenue growth for Imaging Components, offsetting weakness in the security and tube businesses," Wilson said. (For comparison purposes, a quarterly breakout of the Imaging Components segment financials for fiscal years 2014, 2013 and 2012 is attached.)

Other
The company's Other category, including the Varian Particle Therapy business and the Ginzton Technology Center, recorded second quarter revenues of $6 million versus $20 million in the year-ago quarter.  Gross orders for the Other category were $60 million for the second quarter, up from less than $1 million in the year-ago quarter.  The company recorded orders for proton installations at the Cincinnati Children's Hospital Medical Center in Ohio and at the Paul Scherrer Institute in Switzerland.  "This business gained good momentum during the quarter," Wilson said.

Outlook
"The company is continuing to execute well, and our businesses remain on track to reach our fiscal year 2014 growth targets," said Wilson.  "For the fiscal year, we continue to believe that total company revenues could increase by about six to eight percent over the prior fiscal year.  We expect net earnings per diluted share for the fiscal year, including the $0.16 effect of the patent litigation settlement, to be in the range of $4.06 to $4.18. We expect total company revenues for the third quarter of fiscal year 2014 to increase in the range of five to six percent.  We expect net earnings per diluted share for the third quarter to be in the range of $1.06 to $1.10."

Investor Conference Call
Varian Medical Systems is scheduled to conduct its second quarter fiscal year 2014 conference call at 2 p.m. PT today.  To hear a live webcast or replay of the call, visit the investor relations page on the company's web site at www.varian.com/investor where it will be archived for a year.  To access the call via telephone, dial 1-877-869-3847 from inside the U.S. or 1-201-689-8261 from outside the U.S.  The replay can be accessed by dialing 1-877-660-6853 from inside the U.S. or 1-201-612-7415 from outside the U.S. and entering confirmation code 13578961.  The telephone replay will be available through 5 p.m. PT, Friday, April 25, 2014.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing software and workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications.  Varian Medical Systems employs approximately 6,500 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as our Edge™ radiosurgery system, TrueBeam™ and radiographic flat panel detectors, image-guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms "could," "should," "believe," "expect," "continue," "maintain," "outlook," "targets," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include global economic conditions; the impact of  the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company's products; the company's ability to develop, commercialize, and deploy new products such as the TrueBeam platform; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges associated with the successful commercialization of the company's particle therapy business; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by purchasers of certain X-ray products, including those located in Japan; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

A summary of earnings and other financial information follows.

 






Varian Medical Systems, Inc. and Subsidiaries
 Condensed Consolidated Statements of Earnings
 (Unaudited)

 



 

 

(Dollars and shares in millions, except per share amounts)


Q2 QTR

2014


Q2 QTR

2013 (1)


Q2 YTD

2014


Q2 YTD

2013 (1)




Gross orders

$

877.7


757.7


1,533.1


1,409.4




  Oncology Systems


613.0


576.9


1,146.3


1,085.7




  Imaging Components


205.0


180.1


326.4


322.3




  Other


59.7


0.7


60.4


1.4
















Net orders


818.6


735.8


1,427.6


1,355.0




  Oncology Systems


559.1


555.1


1,048.7


1,032.0




  Imaging Components


200.6


180.0


319.3


321.6




  Other


58.9


0.7


59.6


1.4
















Order Backlog


2,806.6


2,752.6


2,806.6


2,752.6
















Revenues


778.5


768.4


1,490.0


1,446.8




  Oncology Systems


603.1


581.8


1,144.5


1,106.1




  Imaging Components


169.0


166.4


330.2


316.4




  Other


6.4


20.2


15.3


24.3
















Cost of revenues


450.2


448.8


852.1


836.1
















Gross margin


328.3


319.6


637.9


610.7




  As a percent of revenues


42.2%


41.6%


42.8%


42.2%
















Operating expenses












  Research and development 


60.7


50.9


118.7


98.0




  Selling, general and administrative 


115.0


113.0


224.6


219.5




  Litigation Settlement 


25.1


-


25.1


-
















Operating earnings


127.5


155.7


269.5


293.2




  As a percent of revenues


16.4%


20.3%


18.1%


20.3%
















Interest income, net


0.6


0.6


1.0


1.3




Earnings before taxes


128.1


156.3


270.5


294.5




Taxes on earnings


35.4


43.5


79.8


86.4




Net earnings

$

92.7


112.8


190.7


208.1




  As a percent of revenues


11.9%


14.7%


12.8%


14.4%
















Net earnings per share – basic

$

0.89


1.04


1.82


1.91
















 Net earnings per share – diluted


0.88


1.02


1.79


1.88
















Shares used in the calculation of net earnings per share:    












Average shares outstanding - basic


104.2


108.8


105.0


109.0




Average shares outstanding - diluted


105.4


110.7


106.4


110.9
















(1)

Prior period numbers have been recast to conform to the segment reporting change.

 

 

 

Varian Medical Systems, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets






(In thousands)


March 28,  


September 27,

2014

     2013  (1)

(Unaudited)


Assets





Current assets





    Cash and cash equivalents

$

938,997

$

1,117,861

    Short-term investment


79,444


62,700

    Accounts receivable, net


786,029


698,254

    Inventories                                       


561,194


535,223

    Deferred tax assets and other                                


312,640


290,745

Total current assets                                       


2,678,304


2,704,783






Property, plant and equipment                                             


750,109


715,991

    Accumulated depreciation and amortization                    


(424,267)


(400,660)

Property, plant and equipment, net                         


325,842


315,331






Goodwill


226,829


225,335

Other assets                                                    


244,863


223,025

Total assets                                              

$

3,475,838

$

3,468,474






Liabilities and Stockholders' Equity





Current liabilities                                                        





    Accounts payable                                             

$

170,364

$

194,272

    Accrued expenses                                             


370,525


320,884

    Deferred revenues                                              


418,247


389,479

    Advance payments from customers                              


169,905


160,644

    Product warranty                                                        


49,445


39,050

   Current maturities of long-term debt                              


56,250


56,250


Total current liabilities                                  


1,234,736


1,160,579

Other long-term liabilities


149,586


144,048

Long-term debt                                                             


412,500


450,000

Total liabilities                                          


1,796,822


1,754,627






Stockholders' Equity





Common stock


104,019


106,491

Capital in excess of par value


650,684


637,084

Retained earnings and accumulated other comprehensive loss 


924,313


970,272

Total stockholders' equity                                 


1,679,016


1,713,847

Total liabilities and stockholders' equity              

$

3,475,838

$

3,468,474



(1)

The condensed consolidated balance sheet as of September 27, 2013 was derived from audited financial statements as of that date. 

 

Varian Medical Systems, Inc. and Subsidiaries

Imaging Components

(Unaudited)







FY 2014


(In Millions)


Q114

Q214



FY 2014


Gross Orders

$

121.4

205.0



326.4


Net Orders


118.7

200.6



319.3


Revenues


161.2

169.0



330.2


Gross Margin                              

$

66.6

70.2



136.8



%

41.3

41.5



41.4


Operating Earnings                              

$

40.7

42.2



82.9















FY 2013


(In Millions)


  Q113

Q213

Q313

Q413

FY 2013


Gross Orders

$

142.2

180.1

144.6

201.3

668.2


Net Orders


141.6

180.0

143.1

201.2

665.9


Revenues


150.0

166.4

158.2

167.3

641.9


Gross Margin                              

$

61.2

70.4

64.8

71.7

268.1



%

40.8

42.3

41.0

42.8

41.8


Operating Earnings                              

$

35.2

43.5

40.2

46.7

165.6















FY 2012


(In Millions)


Q112

Q212

Q312

Q412

FY 2012


Gross Orders

$

120.9

174.6

126.5

174.4

596.4


Net Orders


120.5

174.5

126.2

174.3

595.5


Revenues


128.1

139.8

152.4

160.1

580.4


Gross Margin                              

$

50.4

58.9

66.2

66.9

242.4



%

39.3

42.1

43.4

41.8

41.8


Operating Earnings                              

$

28.4

34.0

39.0

41.1

142.5


















 

FOR INFORMATION CONTACT:

Elisha Finney (650) 424-6803
[email protected]

Spencer Sias (650) 424-5782
[email protected]

SOURCE Varian Medical Systems

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Advances in technology and ubiquitous connectivity have made the utilization of a dispersed workforce more common. Whether that remote team is located across the street or country, management styles/ approaches will have to be adjusted to accommodate this new dynamic. In his session at 17th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., focused on the challenges of managing remote teams, providing real-world examples that demonstrate what works and what do...
CIOs and those charged with running IT Operations are challenged to deliver secure, audited, and reliable compute environments for the applications and data for the business. Behind the scenes these tasks are often accomplished by following onerous time-consuming processes and often the management of these environments and processes will be outsourced to multiple IT service providers. In addition, the division of work is often siloed into traditional "towers" that are not well integrated for cro...
The principles behind DevOps are not new - for decades people have been automating system administration and decreasing the time to deploy apps and perform other management tasks. However, only recently did we see the tools and the will necessary to share the benefits and power of automation with a wider circle of people. In his session at DevOps Summit, Bernard Sanders, Chief Technology Officer at CloudBolt Software, explored the latest tools including Puppet, Chef, Docker, and CMPs needed to...
Sensors and effectors of IoT are solving problems in new ways, but small businesses have been slow to join the quantified world. They’ll need information from IoT using applications as varied as the businesses themselves. In his session at @ThingsExpo, Roger Meike, Distinguished Engineer, Director of Technology Innovation at Intuit, showed how IoT manufacturers can use open standards, public APIs and custom apps to enable the Quantified Small Business. He used a Raspberry Pi to connect sensors...
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, will discuss how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved effi...
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, will discuss using predictive analytics to ...
The cloud promises new levels of agility and cost-savings for Big Data, data warehousing and analytics. But it’s challenging to understand all the options – from IaaS and PaaS to newer services like HaaS (Hadoop as a Service) and BDaaS (Big Data as a Service). In her session at @BigDataExpo at @ThingsExpo, Hannah Smalltree, a director at Cazena, will provide an educational overview of emerging “as-a-service” options for Big Data in the cloud. This is critical background for IT and data profes...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
Father business cycles and digital consumers are forcing enterprises to respond faster to customer needs and competitive demands. Successful integration of DevOps and Agile development will be key for business success in today’s digital economy. In his session at DevOps Summit, Pradeep Prabhu, Co-Founder & CEO of Cloudmunch, covered the critical practices that enterprises should consider to seamlessly integrate Agile and DevOps processes, barriers to implementing this in the enterprise, and pr...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection.
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...
SYS-CON Events announced today that VAI, a leading ERP software provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. VAI (Vormittag Associates, Inc.) is a leading independent mid-market ERP software developer renowned for its flexible solutions and ability to automate critical business functions for the distribution, manufacturing, specialty retail and service sectors. An IBM Premier Business Part...
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...